S1 Data - by Guoqing Meng (4669774)

Subjects:

Differential counts of leukocytes in mouse BALF. by Guoqing Meng (4669774)

Subjects:

Microscopic examination of M07 adhesion to Caco-2 cells (400x). by Guoqing Meng (4669774)

Subjects:

Viability of M07 after co-incubation with GI fluid (Log CFU/mL). by Guoqing Meng (4669774)

Subjects:

Schematic of the OVA-induced asthma mouse model protocol. by Guoqing Meng (4669774)

Subjects:

Levels of pro- and anti-inflammatory cytokines in BALF. by Guoqing Meng (4669774)

Subjects:

Representative sections of HE-stained lung tissue from different groups under light microscopy(400X). by Guoqing Meng (4669774)

Subjects:

Socio-demographic and medical characteristics of patients with liver cancer. by Ayana Ablayeva (22103708)

Subjects:

Data cleaning and preparation algorithm. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. by Ayana Ablayeva (22103708)

Subjects:

OPV coverage by nationwide and at study areas (as per enrollment period). by Zahid Hasan Khan (6281396)

Subjects:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Reasons given by parents/guardians of incompletely vaccinated children (Zero-dose and one-dose OPV vaccination). by Zahid Hasan Khan (6281396)

Subjects:

Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Distribution of background characteristics of the study participants (N = 18255). by Zahid Hasan Khan (6281396)

Subjects: